The webinar will provide an assessment of the June 13, 2013 Supreme Court opinion in Association for Molecular Pathology v. Myriad Genetics Inc. The court considered a fundamental question: Are human genes patentable? But the patent community had a broader concern-the high court's recent statements that seem to question patent eligibility on a number of other fronts. Did the justices limit their review or did they deal a significant blow to a broad swath of patents?
WilmerHale Partner Thomas Saunders will serve on a panel to review the legal arguments and gauge the potential impact on biotechnology and other markets.